Skip to main content

High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.

Publication ,  Journal Article
Krown, SE; Mintzer, D; Cunningham-Rundles, S; Niedzwiecki, D; Krim, M; Einzig, AI; Gabrilove, JL; Shurgot, B; Gessula, J
Published in: Cancer Treat Rep
January 1987

A total of 22 patients with advanced measurable colorectal carcinoma were treated with human lymphoblastoid interferon, 15 X 10(6) U/m2 im 3 times a week, in a trial designed to evaluate therapeutic activity, toxic effects, and biological response modification. One partial response (4.5% response rate) was observed which lasted 4 months. Sixty-eight percent of the patients required dose reduction for excessive toxicity, primarily constitutional symptoms. One patient developed phenobarbital toxicity, a previously undescribed side effect thought to be related to interferon-induced depression of hepatic microsomal enzymes required for drug metabolism. Treatment was associated with an increase in peripheral blood natural killer (NK) cell activity and the activity of an interferon-induced enzyme, 2'-5' oligoadenylate synthetase. The increase in NK cell activity was observed only in patients whose pretreatment NK cell activity was below normal. No induction of serum factors inducing differentiation of myeloid leukemic cell lines was documented. We conclude that human lymphoblastoid interferon, at the dose and schedule tested, has minimal antitumor activity as a single agent in advanced colorectal cancer and induces unacceptable toxicity in the majority of such patients. Recent literature suggesting a possible role for interferon alpha in combination with other drugs in the treatment of colorectal cancer is discussed.

Duke Scholars

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

January 1987

Volume

71

Issue

1

Start / End Page

39 / 45

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lymphocytes
  • Killer Cells, Natural
  • Interferon Type I
  • Humans
  • Female
  • Colonic Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krown, S. E., Mintzer, D., Cunningham-Rundles, S., Niedzwiecki, D., Krim, M., Einzig, A. I., … Gessula, J. (1987). High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep, 71(1), 39–45.
Krown, S. E., D. Mintzer, S. Cunningham-Rundles, D. Niedzwiecki, M. Krim, A. I. Einzig, J. L. Gabrilove, B. Shurgot, and J. Gessula. “High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.Cancer Treat Rep 71, no. 1 (January 1987): 39–45.
Krown SE, Mintzer D, Cunningham-Rundles S, Niedzwiecki D, Krim M, Einzig AI, et al. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep. 1987 Jan;71(1):39–45.
Krown SE, Mintzer D, Cunningham-Rundles S, Niedzwiecki D, Krim M, Einzig AI, Gabrilove JL, Shurgot B, Gessula J. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep. 1987 Jan;71(1):39–45.

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

January 1987

Volume

71

Issue

1

Start / End Page

39 / 45

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lymphocytes
  • Killer Cells, Natural
  • Interferon Type I
  • Humans
  • Female
  • Colonic Neoplasms